clinical advisory board

Stefan Schreiber, MD

University Medical Center Schleswig-Holstein
Department of Internal Medicine I

Professor Schreiber was born in 1962 and received medical degrees in 1988 at University of Hamburg. He is a certificated internist and gastroenterologist. Following a postdoctoral research fellowship in the Departments of Gastroenterology at Washington University (St. Louis, MO) and University of Pennsylvania (Philadelphia, PA) he became junior Faculty in the Department of Gastroenterology at the Charité University Hospital in Berlin, Germany. In 1996 he assumed the position of an associated professor in the Hospital for General Internal Medicine at the University Hospital Schleswig-Holstein (UKSH), Kiel University, Germany.

Stefan Schreiber´s present position is a Full Professor of Medicine. He is the director of the Department of Internal Medicine I and head of the Institute of Clinical Molecular Biology, both at Kiel University. Moreover, he is the speaker of the German DFG cluster of excellence “Precision Medicine in Chronic Inflammation”, PMI.

His research interests include the molecular genetics and pathophysiology of chronic intestinal inflammation, the clinical development of new therapies for IBD and the discovery of mechanisms that control ageing. Memberships in professional societies include the American Gastroenterological Association, the European Society of Clinical Investigation, the Scientific Committee of the German Crohn’s and Colitis Foundation, the German Society for Internal Medicine and the German Society for Gastrointestinal and Metabolic Disorders. Professor Schreiber has been an invited lecturer and held chairmanships at multiple national and international meetings. He is joint editor of some famous international journals in IBD and genetics and has to his credit more than 1000 original publications in different leading scientific journals.

Scroll to Top

Contact Us

TL1A and IL-23

Morphic is leveraging its structural biology expertise and medicinal chemistry capabilities to develop small molecule therapeutic candidates against non-integrin targets including TL1-A and IL-23. Inhibition of these pathways have potential as treatments for IBD through monotherapy and possibly in combination with other IBD treatment mechanisms including α4β7 inhibition.

α5β1

Morphic is developing small molecule inhibitors of the integrin α5β1 based on research demonstrating that fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation. Potential indications include severe pulmonary hypertensive disease including pulmonary arterial hypertension.

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8 (MORF-088)

Morphic is developing small molecule inhibitors of the integrin αvβ8 for potential uses in myelofibrosis and a combination immuno-oncology approach for the treatment of solid tumors. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can drive increased platelet production and potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.